JPMorgan lifts target for Biogen stock to USD 300.00

Published on 10/17/2026 at 20:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen's next earnings date is October 28, 2026. Biogen stock costs EUR 208.30 on October 16, 2026, plus 0.58 percent versus the Tradegate close.

Analyst target and earnings date

JPMorgan raised its Biogen target to USD 300.00 on October 12, 2026.
Biogen's next earnings date is October 28, 2026.
Biogen stock costs EUR 208.30 at 5:31 p.m. CEST on October 16, 2026, plus 0.58 percent versus the Tradegate close of that date.
Biogen had a USD 34.4 billion market capitalization and a P/E ratio of 41.18 on October 16, 2026.

Architektur-Render eines modernen Biotech-Campus mit geschwungener Glasfassade und Wasserelement — Biogen Inc. modernes Biotech-Hauptquartier als futuristisches gläsernes Architektur-Render mit Grünanlagen ISIN US09062X1037, Illustration mit AI erstellt.

JPMorgan raised its Biogen target from USD 210.00 to USD 300.00 and upgraded the stock from Neutral to Overweight on October 12, 2026, according to CNBC. Against Biogen's USD 232.65 Nasdaq price on October 16, 2026, the target stood 28.93 percent higher. Biogen's euro price stood at EUR 208.30 on October 16, 2026 at 5:31 p.m. CEST, plus 0.58 percent versus the Tradegate close of that date.

October 28 earnings date

Biogen's next earnings report is scheduled for October 28, 2026, according to Charlotte Observer. The date gives the market a defined checkpoint after the recent analyst revisions, while the report itself will provide the next company-specific operating figures.

Quarterly revenue rose 3.40 percent

Biogen reported revenue of USD 2.74 billion and earnings per share of USD 3.60 for the quarter ended June 30, 2026, according to MarketBeat. Revenue was 3.40 percent higher than in the same quarter of 2025, while earnings per share exceeded the USD 2.94 consensus estimate by USD 0.66.

Valuation and trading comparison

Biogen had a USD 34.4 billion market capitalization and a P/E ratio of 41.18 on October 16, 2026. The company reported no dividend yield in the same market snapshot, while its 52-week range ran from USD 138.00 to USD 240.99.

Comparison with peers

Biogen Inc. (Nasdaq, USD): plus 0.58 percent, P/E 41.18, market capitalization USD 34.4 billion
Amgen Inc. (Nasdaq, USD): minus 0.35 percent, P/E 26.88, market capitalization USD 233.8 billion
Gilead Sciences, Inc. (Nasdaq, USD): minus 0.75 percent, P/E minus 58.50, market capitalization USD 193.7 billion

Price position for investors

The Tradegate quotation places Biogen below its USD 240.99 52-week high in the company's home currency, while the Nasdaq price remained separate from the euro quotation used for German investors. The analyst target and the October 28 reporting date are the next dated reference points for the stock.

Biogen's EUR 208.30 price was last available at Tradegate on October 16, 2026 at 5:31 p.m. CEST, 0.58 percent above the Tradegate close of October 16, 2026.